


FIG. 1

A



B




FIG. 2





FIG. 3

A



B




FIG. 4





FIG.5

A



B




FIG.6




FIG. 7




FIG.8




FIG.9




FIG.10




FIG.11




FIG.12




FIG.13




FIG. 14A

	Kabat:	H52	H52a	H53	H54	H55	H56	H57	H58	Biacore binding
H2:		T	-	N	G	G	I	T	Y	
Diversification		X	-	X	G	G	X	T	X	
scFv clones:										
VH5/VL1-H2-H1		S					K			=
VH5/VL1-H2-D1				S			K			-
VH5/VL1-H2-B1				M			K			-
VH5/VL1-H2-C3				R			K			-
VH5/VL1-H2-A3							K			=/+
VH5/VL1-H2-C1				T			D			-
VH5/VL1-H21-C2		N		T			G			=
VH5/VL1-H2-G2				T			T			=
VH5/VL1-H2-B3				T			R			=/+
VH5/VL1-H2-E1				T			S			-
VH5/VL1-H2-G1				K			K		F	-
VH5/VL1-H2-E3		N		A			S		L	0

KEYS:

(-) weaker off-rate

(=) off-rate similar to H5/L1 parental scFv

(+) better off-rate

(++) significantly better off-rate

(0) no binding

(ND) not determined

(X) diversity: NNK – all 20 amino-acids

FIG.14B

	Kabat:	L92	L93	L94	L95	L96	Biacore binding
L3:		S	H	V	P	L	
Diversification:		X	X	X	P	x	
ScFv clones:							
VH5/VL1-L3-H7			L	L			++
VH5/VL1-L3-F9		T	Y	M			++
VH5/VL1-L3-B8		T	Y	N			++
VH5/VL1-L3-G8		T	Y	L			++
VH5/VL1-L3-D8		T	K	L			+
VH5/VL1-L3-E8			Y	L			+
VH5/VL1-L3-A9			L	M		I	ND
VH5/VL1-L3-B9			Y	I			ND
VH5/VL1-L3-C9		T	Y	Y			++
VH5/VL1-L3-G7		T	F	L			++
VH5/VL1-L3-F8			Y	S			0
VH5/VL1-L3-C8		T	Y	L		I	++
VH5/VL1-L3-B10			K	L			+
VH5/VL1-L3-D9		S	X	M		L	++

KEYS:

(-) weaker off-rate

(=) off-rate similar to H5/L1 parental scFv

(+) better off-rate

(++) significantly better off-rate

(0) no binding

(ND) not determined


FIG.15


FIG.16


FIG.17

	Human FAB HC/LC SEQ ID NO:	Human IgG1 HC/LC SEQ ID NO:	Human monovalent BEAT® HC1/HC2/LC SEQ ID NO:	Human IgG4 HC/LC SEQ ID NO:
VH5/VL1-B3G8- G29A	206/207	198/199	227/228/229	214/215
VH5/VL1-B3C9- G29A	208/209	200/201	230/231/232	216/217
VH5/VL1-G8- G29A	202/203	194/195	221/222/223	210/211
VH5/VL1-C9- G29A	204/205	196/197	224/225/226	212/213
VH5/VL1	233/234	10/30	218/219/220	235/236

FIG.18A

FAB	Ka human CCR6	Kd human CCR6	KD human CCR6	Ka cynomolgus CCR6	Kd cynomolgus CCR6	KD cynomolgus CCR6
VH5/VL1-B3G8-G29A	6.46e6	3.39e-3	526 pM	1.72e6	2.02e-3	1.17 nM
VH5/VL1-B3C9-G29A	6.96e6	3.79e-3	544 pM	1.83e6	2.25e-3	1.23 nM
VH5/VL1-G8-G29A	2.65e6	2.66e-3	1.0 nM	8.97e5	1.96e-3	2.19 nM
VH5/VL1-C9-G29A	2.66e6	3.41e-3	1.28 nM	8.75e5	2.44e-3	2.79 nM
VH5/VL1	1.58e6	3.11e-2	19.6 nM	7.44e5	2.50e-2	33.6 nM

FIG.18B



20/20

FIG.19

